Fig. 6: Kaplan–Meier plots of survival in different TCR clonality and mTBI subgroups of the sintilimab group. | Nature Communications

Fig. 6: Kaplan–Meier plots of survival in different TCR clonality and mTBI subgroups of the sintilimab group.

From: Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Fig. 6: Kaplan–Meier plots of survival in different TCR clonality and mTBI subgroups of the sintilimab group.

a Overall survival. b Progression-free survival. The high- or low- level groups of TCR clonality or mTBI are split by the respective median value. Group A: high TCR clonality and high mTBI; Group B: high TCR clonality and low mTBI; Group C: low TCR clonality and high mTBI; Group D: low TCR clonality and low mTBI. P-values were based on a two-sided Wald test. Source data are provided as a Source Data file.

Back to article page